(Q38107546)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Zhiguang Zhou

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Lin Yang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

19 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

21-29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683065%20AND%20SRC:MED&resulttype=core&format=json

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin-induced hemolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Direct association of adenosine deaminase with a T cell activation antigen, CD26

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

The structure and function of CD26 in the T-cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Endothelial dysfunction: a marker of atherosclerotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation--the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

The impact of blood coagulability on atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Sitagliptin exerts an antinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063

Dipeptidyl peptidase expression during experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12063